Increased serum remnant lipoproteins in patients with apolipoprotein E7 (apo E Suita).
Apolipoprotein (apo) E7 was originally identified by Yamamura et al. in subjects with atherosclerotic cardiovascular diseases (J. Clin. Invest. 1984;74:1229). However, the lipoprotein abnormalities associated with apo E7 phenotype have not been elucidated. In the current study, to clarify the physiological roles of apo E7, lipoprotein abnormalities were studied in 12 apo E7 heterozygotes. A total of seven subjects were hyperlipidemic and five subjects were normolipidemic. The apo E phenotype was apo E7/3 in 11 subjects and apo E7/4 in one subject. Polymerase chain reaction revealed that all of the subjects with apo E7 phenotype had the same mutation as that of apo E(Suita) as reported previously (J. Biochem. 1989;105:249). All the hyperlipidemic subjects were over 40 years of age and two of them also had and severe coronary heart disease. Ultracentrifugal analysis revealed that the cholesterol level both in very low density lipoprotein and in intermediate density lipoprotein (IDL) was substantially higher in hyperlipidemic apo E7 heterozygotes, compared with control subjects and that the IDL cholesterol was also increased even in normolipidemic apo E7 heterozygotes. Polyacrylamide gel electrophoresis of lipoproteins showed a midband, which implies the increase of remnant lipoproteins, in 11 subjects out of 12, irrespective of the presence or absence of hyperlipoproteinemia. In two cases, a broad beta pattern was observed similar to that seen in type III hyperlipoproteinemia. Dietary therapy was dramatically effective for the treatment of hyperlipidemia in patients with apo E7. These findings confirm that apo E is crucial for remnant lipoprotein metabolism and that apo E7 is related to the increase in serum remnant lipoproteins, which leads to hyperlipoproteinemia in association with obesity, aging and impaired glucose metabolism.
Yanagi
K
K
The Second Department of Internal Medicine, Osaka University Medical School, Suita, Japan.
Yamashita
S
S
Hiraoka
H
H
Ishigami
M
M
Kihara
S
S
Hirano
K
K
Sakai
N
N
Nozaki
S
S
Funahashi
T
T
Kameda-Takemura
K
K
Kubo
M
M
Tokunaga
K
K
Matsuzawa
Y
Y
D000328:Adult; D000368:Aged; D053318:Apolipoprotein E3; D001057:Apolipoproteins E / Q000097:blood* / Q000235:genetics; D002352:Carrier Proteins / Q000097:blood; D002784:Cholesterol / Q000097:blood; D053480:Cholesterol Ester Transfer Proteins; D015243:Cholesterol, VLDL / Q000097:blood; D004247:DNA / Q000032:analysis; D004591:Electrophoresis, Polyacrylamide Gel; D006023:Glycoproteins; D006579:Heterozygote; D006801:Humans; D006949:Hyperlipidemias / Q000178:diet therapy / Q000235:genetics; D008074:Lipoproteins / Q000097:blood*; D008875:Middle Aged; D016133:Polymerase Chain Reaction
D053318:Apolipoprotein E3; D001057:Apolipoproteins E; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D015243:Cholesterol, VLDL; D006023:Glycoproteins; D008074:Lipoproteins; C049579:apolipoprotein E7, human; C030104:lipoprotein cholesterol; D004247:DNA; D002784:Cholesterol